EPB158	Low level of virologic failure and resistance in ART-experienced, integrase inhibitor-naïve participants receiving dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) combined regimens: 10-year follow-up in the SAILING Study	E-poster	ART in highly treatment-experienced persons
EPB159	Safety and efficacy of switching to BIC/FTC/TAF plus DOR in HIV-infected patients with multiclass-resistant virus	E-poster	ART in highly treatment-experienced persons
EPB160	Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1: week 240 results of the Phase 3 BRIGHTE study	E-poster	ART in highly treatment-experienced persons
PESUB20	Ibalizumab long-term efficacy is not impacted by partially active antiretrovirals	Poster exhibition	ART in highly treatment-experienced persons
EPB146	Cost-effective continuous flow synthesis of HIV second and third generation integrase inhibitor drugs: a step towards local API manufacturing in Africa	E-poster	ART in acute, first- and second-line therapies
EPB147	Treatment experience of single-tablet dolutegravir/lamivudine in the United States: results from the 'real-world outcomes with dolutegravir-based two-drug-regimens for the treatment of HIV-1' (TANDEM study)	E-poster	ART in acute, first- and second-line therapies
EPB148	Advanced HIV infection in the US: immune response to ART initiation	E-poster	ART in acute, first- and second-line therapies
EPB149	Higher CD4/CD8 ratio recovery observed among people living with HIV started with integrase strand transfer inhibitors	E-poster	ART in acute, first- and second-line therapies
EPB150	Long-term integrated analysis of B/F/TAF in treatment-naïve adults with HIV through five years of follow-up	E-poster	ART in acute, first- and second-line therapies
EPB151	A pilot study of the impact of a rapid ART initiation in advanced HIV disease	E-poster	ART in acute, first- and second-line therapies